CD Biosciences Releases Drosophila CRISPR/Cas9 Genome Editing to Study Gene Function and Drug Screening
CD Biosciences Drosophila Center focuses on micro-injection, genome editing, cell engineering, genetics, metabolism, neurobiology and other fields. With a mission to provide high-quality and affordable Drosophila products and services, CD BioSciences with a team of experienced experts develops solutions by precise genetic modification of Drosophila as humanized models, as well as diverse phenotypes analysis for fundamental research and drug discovery. Recently, CD Biosciences announced the release of its drosophila Crispr/cas9 genome editing to study disease and development mechanisms, gene function, drug screening etc.
Compared with ZFN and TALEN, the CRISPR/Cas9 system has obvious advantages in gene editing in Drosophila: (1) more potential PAM sites can be found in the genome; (2) CD Biosciences provides Cas9 and sgRNA in Drosophila The germline expression of the mutant strain greatly improves the efficiency; (3) The CRISPR/Cas9 system is used to edit the genes of Drosophila with a high success rate. The CRISPR/Cas9 system has been effectively used to achieve loss-of-function gene knockout with mutagenesis rates as high as 75-99%.
CD BioSciences, as one of the designers of transgenic Drosophila strains, uses leading technologies to facilitate exploration in the field of life sciences, its services range from oligonucleotide customization to CRISPR editing, and off-target effect analysis to meet clients' individual research needs.
CD Biosciences' Drosophila CRISPR/Cas9 genome editing services include:
Production of high-quality custom CRIPSR oligonucleotides, including sgRNA, ssDNA and dsDNA, on advanced platforms.
One-stop CRISPR/Cas9 Gene Knock-out (KO) Drosophila services, allowing to create own Drosophila transformants.
CRISPR/Cas9 uses a new model of DNA-RNA recognition for gene editing, greatly reducing the difficulty of design and the threshold of gene knock-in.
Drosophila CRISPRi/CRISPRa are flexible tools for studying gene function and metabolic networks, enabling conditional genome-wide activation or transcriptional disruption of target genes.
CD Biosciences offers a variety of sequencing platforms and analysis algorithms for off-target analysis of the CRISPR/Cas9 system in Drosophila, including PCR-based and next-generation sequencing technologies.
“We offer comprehensive CRISPR Drosophila services including design, cloning, microinjection, screening, validation and population construction to bring you gene-edited Drosophila.” said Marcia Brady, the marketing director of CD Biosciences, she also added, “In our Drosophila center, the Cas9 protein of these transgenic Drosophila strains can be specifically expressed in germ cells according to your needs, and Cas9 transgenic lines with different chromosomes are available.”
About CD BioSciences
With a mission to provide high-quality and affordable Drosophila products and services, CD BioSciences with a team of experienced experts, develops solutions by precise genetic modification of Drosophila as humanized models, as well as diverse phenotypes analysis for fundamental research and drug discovery.
